HCG Q2 FY26 results: consolidated revenue up 17%, PAT dips YoY

Exceptional itemResults restatedResults View source PDF Explain this filing

HCG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹749.95

prior close

₹740.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%-0.3% vs market

Hospital peers, median of 18sector-0.5%+0.1% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.2

15m

-0.0

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4-0.1-0.3-0.5+0.1

Next day

-1.9-0.2-1.7-0.6-1.3

-1.8+0.4-2.3+0.5-2.3

-2.0-0.4-1.6-1.0-1.0

-0.2-0.6+0.4-1.8+1.6

-0.9-0.9-0.0-1.1+0.2

-5.0-3.0-2.0-1.5-3.5

15d

-4.7-3.9-0.8-3.0-1.7

-4.0-4.8+0.8-2.5-1.6

-10.7-7.8-2.9-7.0-3.7

-22.4-7.2-15.2-8.6-13.8

UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 18Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

HCG reported Q2 FY26 standalone revenue of Rs. 344.41 crore (up 4.9% YoY) and consolidated revenue of Rs. 646.16 crore (up 17% YoY). Standalone Q2 PAT was Rs. 10.78 crore vs Rs. 17.95 crore restated YoY. Consolidated H1 PAT was Rs. 46.68 crore. Board allotted 7,537 ESOP shares and approved Rs. 7 crore investment in Cancer Care Kenya.

Likely market impact

Revenue grew at consolidated level but standalone profit declined YoY on higher ESOP settlement and exceptional costs.